Provided by Tiger Trade Technology Pte. Ltd.

Corvus Pharmaceuticals

10.96
+0.03000.27%
Volume:580.12K
Turnover:6.36M
Market Cap:918.09M
PE:-17.53
High:11.11
Open:11.11
Low:10.82
Close:10.93
52wk High:26.95
52wk Low:6.39
Shares:83.77M
Float Shares:74.12M
Volume Ratio:1.14
T/O Rate:0.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6252
EPS(LYR):-0.5320
ROE:-35.43%
ROA:-21.66%
PB:4.07
PE(LYR):-20.60

Loading ...

Mizuho Securities Sticks to Their Buy Rating for Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
Jun 12

BUZZ-U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj

Reuters
·
Jun 09

BUZZ-U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental

Reuters
·
Jun 09

BUZZ-Corvus rises as it invests in China partner to advance skin, asthma drug trials

Reuters
·
Jun 09

Corvus Pharmaceuticals - Invests $5 Mln in Angel Pharmaceuticals Financing

THOMSON REUTERS
·
Jun 09

Press Release: Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Dow Jones
·
Jun 09

Corvus Pharma posts corporate deck highlighting soquelitinib ITK inhibitor program across immune diseases and T‑cell lymphoma

Reuters
·
Jun 04

Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness

Simply Wall St.
·
Jun 02

Top Executive Makes Bold Insider Move on Corvus Pharmaceuticals Stock

TIPRANKS
·
May 21

Corvus CEO Richard Miller reports trust buy of USD 83,112 common shares

Reuters
·
May 21

Corvus Pharmaceuticals presents at Jefferies Global Healthcare Conference

Reuters
·
May 21

Corvus Pharmaceuticals Down Over 11%, On Track for Largest Percent Decrease Since March 2025 -- Data Talk

Dow Jones
·
May 14

Goldman Sachs Sticks to Its Buy Rating for Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 12

Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS

Simply Wall St.
·
May 12

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA) and Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 11

Stock Track | Corvus Pharmaceuticals Plummets 5.76% Intraday on Widening Q1 Loss and Rising R&D Expenses

Stock Track
·
May 08

Corvus Q1 FY26 results: net loss widens to $13.7 million; R&D expense rises to $11.2 million

Reuters
·
May 08

Corvus Pharma Q1 EPS $(0.15), Inline

Benzinga Earnings
·
May 08

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 08

A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board

Simply Wall St.
·
May 03